{"entity":{"id":"nct05320588","kind":"trial","name":"A Study in Patients With Advanced Cancers","aka":["StarBridge-1"],"tldr":"A phase 1/2 trial of BIO-106, Pembrolizumab in metastatic cancer, run by BiOneCure Therapeutics Inc., now recruiting.","summary":"A Study in Patients With Advanced Cancers is a phase 1/2 interventional study registered as NCT05320588 by BiOneCure Therapeutics Inc., with 332 participants planned, started 2022-03-25 and due to reach its primary completion in 2024-04. Interventions recorded: BIO-106, Pembrolizumab. Conditions listed: Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05320588","url":"https://clinicaltrials.gov/study/NCT05320588"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":[],"drugs":["bio-106","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05320588","phase":"1/2","setting":"A Phase 1/2 Study of BIO-106 As Monotherapy or In Combination With Pembrolizumab in Patients With Advanced Cancers (StarBridge-1)","sponsor":"BiOneCure Therapeutics Inc.","participation":[{"nct":"NCT05320588","source":"https://clinicaltrials.gov/study/NCT05320588","fetchedAt":"2026-10-07T16:53:39.725Z","studySha256":"743706cfe79dc29a5af3c55a9adfd9569cdc40e665dddd34f3f039d9c7c7327f","overallStatus":"RECRUITING","lastUpdatePosted":"2022-07-19","leadSponsor":"BiOneCure Therapeutics Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":332,"enrolmentType":"ESTIMATED","siteCount":3,"recruitingSiteCount":3,"countries":["United States"]}],"started":"2022-03-25","startedType":"actual","enrolled":332,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05320588/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"bio-106","kind":"drug","name":"BIO-106","route":"/drugs/bio-106/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}